Dataset Information

Impact of age on thromboembolic events in patients with non-valvular atrial fibrillation.

ABSTRACT:

Background

Age is a well-established risk factor for thromboembolic events in patients with atrial fibrillation (AF). However, the mechanism underlying the association between age and thromboembolic events in AF remains unknown.

Methods

The prognostic value of age as a risk factor for thromboembolic events was analyzed using data from the Korean National Health Insurance Service (NHIS). In a large-scale single-center registry, cardiac hemodynamic parameters were examined to elucidate the cause of increased risk of thromboembolic events in older patients.

Results

NHIS sample cohort data including 5896 patients with AF revealed that the risk of thromboembolic complication differed significantly according to age despite equal CHA₂ DS₂ -VASc score. In the registry of 2801 patients, age showed significant correlations with left atrium (LA) diameter, LA volume, E/e', pulmonary artery pressure, and LA appendage flow velocity. Older patients had a significantly higher prevalence of spontaneous echocontrast (odds ratio [OR] = 1.030; P?2 DS₂ -VASc score did not outperform age to predict thromboembolic events.

Conclusions

Age is a significant risk factor for thromboembolic events in patients with AF, and old age is associated with adverse cardiac hemodynamics. This study suggests that older patients with AF are at high risk of thromboembolic events regardless of CHA₂ DS₂ -VASc score.

SUBMITTER: Kim YG

PROVIDER: S-EPMC6954376 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Impact of age on thromboembolic events in patients with non-valvular atrial fibrillation.

Kim Yun Gi YG Choi Jong-Il JI Boo Ki Yung KY Kim Do Young DY Hong Yeji Y Kim Min Sun MS Lee Kwang-No KN Shim Jaemin J Kim Jin Seok JS Kim Young-Hoon YH

Clinical cardiology 20191115 1

<h4>Background</h4>Age is a well-established risk factor for thromboembolic events in patients with atrial fibrillation (AF). However, the mechanism underlying the association between age and thromboembolic events in AF remains unknown.<h4>Methods</h4>The prognostic value of age as a risk factor for thromboembolic events was analyzed using data from the Korean National Health Insurance Service (NHIS). In a large-scale single-center registry, cardiac hemodynamic parameters were examined to elucid ...[more]

PMID: 31729782

Similar Datasets

Project description:Background:The comparative safety and effectiveness of treatments to prevent thromboembolic complications in atrial fibrillation (AF) remain uncertain. Purpose:To compare the effectiveness of medical and procedural therapies in preventing thromboembolic events and bleeding complications in adults with nonvalvular AF. Data Sources:English-language studies in several databases from 1 January 2000 to 14 February 2018. Study Selection:Two reviewers independently screened citations to identify comparative studies of treatments to prevent stroke in adults with nonvalvular AF who reported thromboembolic or bleeding complications. Data Extraction:Two reviewers independently abstracted data, assessed study quality and applicability, and rated strength of evidence. Data Synthesis:Data from 220 articles were included. Dabigatran and apixaban were superior and rivaroxaban and edoxaban were similar to warfarin in preventing stroke or systemic embolism. Apixaban and edoxaban were superior and rivaroxaban and dabigatran were similar to warfarin in reducing the risk for major bleeding. Treatment effects with dabigatran were similar in patients with renal dysfunction (interaction P > 0.05), and patients younger than 75 years had lower bleeding rates with dabigatran (interaction P < 0.001). The benefit of treatment with apixaban was consistent in many subgroups, including those with renal impairment, diabetes, and prior stroke (interaction P > 0.05 for all). The greatest bleeding risk reduction was observed in patients with a glomerular filtration rate less than 50 mL/min/1.73 m2 (P = 0.003). Similar treatment effects were observed for rivaroxaban and edoxaban in patients with prior stroke, diabetes, or heart failure (interaction P > 0.05 for all). Limitation:Heterogeneous study populations, interventions, and outcomes. Conclusion:The available direct-acting oral anticoagulants (DOACs) are at least as effective and safe as warfarin for patients with nonvalvular AF. The DOACs had similar benefits across several patient subgroups and seemed safe and efficacious for a wide range of patients with nonvalvular AF. Primary Funding Source:Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42017069999).

Dataset Information

Impact of age on thromboembolic events in patients with non-valvular atrial fibrillation.

Background

Methods

Results

Conclusions

Publications

Impact of age on thromboembolic events in patients with non-valvular atrial fibrillation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets